CompletedPhase 2ACTRN12623000593639

Does cannabidiol enhance exercise enjoyment? A randomised controlled trial.

The effect of cannabidiol on affective responses to self-paced aerobic exercise in healthy adults: A randomised, double-blind, placebo-controlled, crossover trial.


Sponsor

The University of Sydney

Enrollment

120 participants

Start Date

Jul 17, 2023

Study Type

Interventional

Conditions

Summary

Physical inactivity is estimated to cause almost one in ten premature deaths worldwide. A pilot clinical trial conducted by the Lambert Initiative (University of Sydney) and scientists at Griffith University found that the non-intoxicating phytocannabinoid, cannabidiol (CBD), had an effect to increase ratings of pleasure during aerobic exercise; specifically, in endurance-trained males running at a fixed, moderate intensity. This initial finding suggests that CBD has the potential to support physical activity (PA) participation. However, further research is required to confirm and better understand the observed effect. The overall objective of this trial is to determine whether CBD can enhance affective responses to self-paced aerobic (running) exercise in recreationally active individuals – and, thus, support PA participation. Participants will complete two treatment sessions involving the oral administration of CBD (150 mg) or a placebo in a randomised, double-blind, crossover design. Affective valance will be measured at baseline (pre-treatment), pre-exercise, at 6-lap intervals throughout a 25-lap run (~10 km) on a standard outdoor athletics track, and post-exercise using validated scales. Exercise enjoyment, motivation to exercise, and exercise self-efficacy will also be assessed. We hypothesise that CBD will increase ratings of pleasure during self-paced aerobic exercise – as well as exercise enjoyment, motivation, and self-efficacy.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Inclusion Criteria3

  • (a) Greater than or equal to 18 years of age
  • (b) Able to perform aerobic exercise as assessed using the ‘Physical Activity Readiness Questionnaire for Everyone ’ (PAR-Q+).
  • (c) Proficient in English (i.e., able to provide informed consent).

Exclusion Criteria7

  • (a) A self-reported history of allergic reaction to cannabis or cannabinoid-containing products
  • (b) A self-reported history of liver disease or renal disease
  • (c) A self-reported or physician-suspected history of drug/alcohol dependence (excluding nicotine dependence)
  • (d) Current suicide ideation (i.e., a score >0 on Question 9 of the 'Patient Health Questionnaire' or at the physician's discretion)
  • (e) Regular (i.e., more than twice weekly) use of cannabis or CBD
  • (f) Unwilling to adhere to trial procedures
  • (g) Pregnant, lactating, or trying to conceive.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

The intervention will be 150 mg of cannabidiol (CBD). Specifically, it will be 2 x soft-gel capsules each containing 75 mg CBD in an oil-based formulation. The capsules will be consumed (once only) vi

The intervention will be 150 mg of cannabidiol (CBD). Specifically, it will be 2 x soft-gel capsules each containing 75 mg CBD in an oil-based formulation. The capsules will be consumed (once only) via oral ingestion under the supervision of an investigator 90 minutes prior to exercise. The exercise task will be a supervised 25-lap (i.e., ~10 km) run on a standard, outdoor athletics track. Each participant will complete two runs – one after each treatment (i.e., CBD and placebo). The runs will be self-paced with participants instructed to minimise the amount of walking they do and run to the same self-selected 'goal' (i.e., either: (a) as fast as possible, (b) as fast as is comfortably possible or (c) at a tolerable pace) on each occasion. They will also be completed in large groups with participants instructed to run in the same ‘social context’ (i.e., either: (a) predominantly alone or (b) predominantly with one partner) on each occasion. Participants will be instructed not to listen to music or consume fluid throughout exercise. The washout period between treatments will be greater than or equal to 7 days.


Locations(1)

QLD, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12623000593639


Related Trials